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Preclimical in vitro and in vivo activity of 5,6-dimethylxanthenone 4acetic
acid
AL Laws, AM Matthew, JA Double and MC Bibby
Clinical Oncology Unit, U'niversity ofBradford, Richmond Road, Bradford BD7 JDP, UK.
Summary 5.6-Dimethylxanthenone4-acetic acid (5.6-MeXAA) is a fused tricyclic analogue of flavone acetic
acid (FAA) which was developed in an attempt to improve on the activity of FAA. Previous studies have
shown 5.6-MeXAA to be curative in 80% of mice bearing colon 38 tumours and 12 times more dose potent
than FAA. This investigation has demonstrated that a murine colon tumour cell line (MAC1SA) is approx-
imately 60 times more sensitive to 5.6-MeXAA than to FAA. although these differences were not seen in three
human cell lines tested. 5,6-MeXAA caused significant blood flow shutdown and haemorrhagic necrosis in
subcutaneous MAC15A tumours in syngeneic and nude hosts. but measurable changes in tumour volume were
seen only in syngeneic hosts. 5,6-MeXAA was inactive against intraperitoneal MACISA but produced
significant anti-tumour effects against the same cell line inoculated via an intravenous route. FAA has been
shown previously to be inactive in this model. Interestingly, the effects against lung colonies were not
accompanied by obvious necrotic changes, suggesting that they may be the result of increased direct
cytotoxicity rather than an indirect host mechanism. Further studies to investigate the effects against systemic
tumour deposits are under way.
Keywords: preclinical studies: in vitro, in vivo. 5.6-dimethvlxanthenone-4acetic acid
Flavone acetic acid (FAA) is a synthetic flavonoid which was
selected for clinical trials on the basis of its anti-tumour
activity against a wide range of murine subcutaneously (s.c.)
transplantable solid tumours which are generally refractive to
conventional cytotoxic agents (Corbett et al., 1986; Plowman
et al., 1986; Bibby et al., 1987). Clinical trials, however,
showed that the promising activity observed in these murine
models was not repeated in cancer patients, as the compound
was found to be inactive against all tumour types tested
(Kerr et al., 1989).
In vitro data suggest that FAA possesses very little direct
cytotoxic activity, requiring long exposure times and high
concentrations to kill any of the cell lines tested (Bibby et al.,
1987; Capolongo et al., 1987; Schroyens et al., 1987), and
therefore an indirect mechanism of action was proposed.
Studies by Bibby et al. (1989a) suggested that tumour site
was important as, although good responses were seen against
s.c. solid tumours, no activity was observed against the same
tumour cells when implanted intraperitoneally (i.p.) or intra-
venously (i.v.) to produce systemic lung deposits. It was
suggested, therefore, that the action of FAA is dependent on
the presence of tumour vasculature, as Bibby et al. (1988)
demonstrated that the response of s.c. tumours to FAA
treatment improved with time as tumour vasculature was
established. Vascular shutdown and reduction in tumour
blood flow have been shown to accompany the anti-tumour
activity (Evelhoch et al., 1988; Bibby et al., 1989b; Hill et al.,
1989; Zwi et al., 1989).
An immunomodulatory effect was also implicated (Ching
and Baguley, 1987; Hornung et al., 1988; Wiltrout et al.,
1988), and previous studies in this laboratory have shown
that the immune status of the mouse is important, as no
objective responses were observed in s.c. tumours trans-
planted in thymectomised and nude mice although haemorr-
hagic necrosis and a reduction in tumour blood flow did
occur (Bibby et al., 1991). Lack of activity in nude mice is
not universal as studies in other laboratories have demon-
strated modest responses in tumours in immune compro-
mised mice (Pratesi et al., 1990; Ching et al., 1992). The
production of both tumour necrosis factor alpha (TNF-a)
(Mahadevan et al., 1990) and plasma nitrite nitrate (Thom-
Correspondence: MC Bibby
Received 26 August 1994: reVised 6 Januar) 1995; accepted 13
January 1995.
sen et al., 1991) has been implicated in FAA-mediated vas-
cular shutdown.
Even though FAA was clinically disappointing, investiga-
tion has continued, because of the unusual mechanism of
action, into the development of a series of analogues. These
are based largely around the structurally related xanthenone
chromophore (Atwell et al.. 1989; Rewcastle et al.. 1989,
1991a-c). From these studies 5,6-dimethylxanthenone-4
acetic acid (5,6-MeXAA, Figure 1) was found to exhibit
increased dose potency against s.c. murine tumours (Rew-
castle et al., 1991a) and was selected for further evaluation
including a pharmacokinetic study (McKeage et al., 1991)
and demonstration of stimulation of nitric oxide production
from activated macrophages (Thomsen et al., 1990, 1991,
1992; Veszelovszky et al., 1993). An earlier study also dem-
onstrated that 56-MeXAA is more effective than FAA at
producing measurable growth delays in colon 38 tumours
growing in nude mice (Ching et al., 1992). On the basis of
these early studies 5,6-MeXAA has been selected for clinical
evaluation by the Cancer Research Campaign and is awaiting
entry into phase I trials.
The aims of the present study were to investigate further
the preclinical activity of 5,6-MeXAA by comparison of its
anti-tumour profile against a panel of cell lines and an exper-
imental colon tumour (MAC15A) with that observed for
FAA, in an attempt to assess the compound's clinical poten-
tial. In order to make a direct comparison with FAA, and
possibly to identify any advantage, the study paid particular
attention to the influence of site and host immune status.
Anti-tumour effects were examined together with a his-
tological evaluation of treated tumours growing at various
sites. The effect of the compound on tumour vasculature was
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evaluated in both imocompetent mice and immuno-
deficient nude mice by a dye perfusion assay designed to
measure tumour blood concentration.
MateraL& and e
Anbnals
Pure-strain NMRI mice aged 6-8 weeks from an inbred
colony and NCR nude mice obtained from the NCI were
used. They received CRM diet (Labsure, Croyden, UK) and
water ad libitum, and were exposed to regular alternate 12 h
cycles of light and dark. Nude mice were housed in isolation
cabinets. All animal experiments were carried out under
appropriate licences issued by the Home Office, London,
UK, and each experimental group contained at least five
animals.
Test compounds
5,6-MeXAA was a gift from the Cancer Research Campaign.
For in vivo use 5,6-MeXAA was made up immediately before
use in physiological saline, at an appropriate concentration
for the desired dose to be administered in 0.lml per lOg
body weight. All treatments were administered i.p.
For in vitro use 5,6-MeXAA and FAA (a gift from Lipha,
Lyon, France) were dissolved to the appropriate concentra-
tion in complete RPMI-1640 (RPMI) tissue culture medium
immediately before use and serially diluted.
Tumour system
The MAC15A ascitic tumour was originally developed from
the solid MAC15 s.c. tumour induced in NMRI mice by
prolonged administration of dimethylhydrazine (Double et
al., 1975). The tumour was routinely passaged as an intra-
peritoneal ascites tumour in NMRI mice. Cells were removed
by aseptic peritoneal washing with physiological saline, estab-
lished in culture or implanted s.c. (I x 106 per mouse), i.p.
(5 x I0W per mouse) and i.v. (I x 10' per mouse) to produce
tumours at various sites.
In vitro studies
Ascitic MAC15A cells, obtained as described above, and
HRT-18 (Tompkins et al., 1974) and HT-29 (Fogh and
Trempe, 1975) cell lines derived from human prnmary
adenocarcinomas of the large bowel, were routinely main-
tained as monolayer cultures in RPMI tissue culture medium
supplemented with 10% fetal calf serum, sodium pyruvate
(I mM), penicillin/streptomycin (50 IU ml', 50pgml-') and
L-glutamine (2 mM) at 37C. K562 human chronic myelo-
genous leukaemia-derived cells (Lozzio and Lozzio, 1975)
were maintained as a suspension culture in complete RPMI.
Subconfluent cells were used for all assays, and all assays
were performed in triplicate. Cytotoxicity was ass over a
range of 5,6-MeXAA or FAA concentrations in a continuous
96h exposure assay. Cell survival was assessed using the
MTT assay (Carmichael et al., 1987) and the IC5 calculated
for each cell type.
Chemotherapy
5,6-MeXAA was given on day 5 after tumour implantation
for all s.c. tumours to allow for vascular development (estab-
lished by histological excamination), and tumour growth was
followed by serial caliper measurements. Mean tumour
volumes on day 5 were similar for both hosts (186mm3,
range 72-405, for nude hosts; and 169mm3, range 72-252,
for NMRI hosts). Anti-tumour activity was assessed by
tumour volume, determined by the formula a' x b/2, where a
is the smaller and b the larger tumour diameter (Geran et al.,
1972). Growth delay was determined by comparison of the
median time taken to reach relative tumour volume 2 of the
treated and control tumours. The significance of these results
was determined by Mann-Whitney statistical analysis.
Anti-tumour activity of i.p. tumours was assessed using
median survival times (MST) of treated and control groups.
Treatment occurred on day 2 following tumour cell implanta-
tion.
For systemic disease treatment occurred 2 days after i.v.
inoculation of MAC15A cells via the tail vein. The effects of
treatment were assessed by two methods: MST of treated vs
controls and a colony counting method. The latter method
involved the sacrifice of all mice on the day of death of the
first control, with the removal ofall lungs. Individual tumour
colonies were counted on all surfaces of the lungs.
Tumour histolog)
Subcutaneous tumours were excised 24 h after treatment,
together with untreated controls, and processed for his-
tological examination. Lungs from mice injected i.v. with
MACl5A cells were also examined. Paraffin-embedded
blocks were sectioned (5 gm) and stained with haematoxylin
and eosin (H&E). The percentage haemorrhagic necrosis
occurring within the tumours was calculated using an image
analysis system (Seescan, Cambridge, UK). Sections through
the centre of each tumour were measured and the total area
calculated. Areas of viable and necrotic tissue were then
determined and the ratio between the two areas calculated.
Tumour bloodperfusion
Tumour blood volume was measured by the Evans blue dye
perfusion technique. Evans blue dye (10mgml-') was
injected i.v. into the tail vein of NMRI and nude mice
bearing MACISA s.c. tumours. Treatment groups received
5,6-MeXAA 2, 4 and 24 h before injection with Evans blue.
Tumours were removed 2 min after injetion and the dye
extracted from tumours using a method based on the study
of Harada et al. (1971).
Statistical analysis ofresults
The significance of the results was determined by the use of
Student's t or Mann-Whitney tests.
Reslts
In vitro studies
IC54 values for the cell lines, MAC15A, K562, HRT-18 and
HT-29 following a continuous % h exposure to 5,6-MeXAA
are shown in Table I. Comparative in vitro IC50 data with
FAA are also presented. MAC15A cells are more sensitive
than the other cell lines tested (IC50, 1.9 ± 1.2pg ml-'), and
over 60 times more sensitive to FAA under the same condi-
tions (ICO, 119 ± 18.6 Lgml-'). The human cell lines derived
from solid tumours showed moderate sensitivity to 5,6-
MeXAA. HT-29 gave an IC_(o value of 70 ± 1.4 Lg ml-' and
HRT-18 a value of 88±22#gml-'. 5,6-MeXAA was
relatively non-cytotoxic to the human leukaemia-derived cell
line K562 (IC50, 241 ± 61).
In vivo studies
Untreated MAC15A s.c. tumours had mean volume doubling
times of 3.5 days and 2.6 days for NMRI and nude mice
Table I In vitrocytotoxicity of5,6-MeXAA and FAA in a continuous
96 h exposure MTT assay
IC50 (g ml-,) IC50 (ggml')
Cell line 5,6-MeXAA FAA
MAC15A 1.9±1.2 119 19
K562 241±61 170±48
HT-29 70± 1 198 30
HRT-18 88±22 85±16
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respectively. The effect of i.p. administered 5,6-MeXAA on
day 5 s.c. MACI5A tumours was significantly different for
NMRI and nude hosts. Growth delay was calculated as the
difference in time taken for the median control and treated
tumours to reach relative tumour volume 2. In nude mice
25mgkg-' 5,6-MeXAA had no statistically significant effect
on tumour growth in two independent experiments (Figure
2a), however on increasing this dose to 30mgkg-' a small
growth delay of 4.2 days was observed but deaths were seen.
5,6-MeXAA showed a highly significant effect against
MAC15A tumours in NMRI mice, with tumour regression
and a 13.3 day growth delay (P<0.01) observed at
28mg kg-' (Figure 2b). A similar delay (16.3 days) was
observed when the experiment was repeated independently.
Histological examination of treated s.c. tumours revealed
large areas of haemorrhagic necrosis 24h after treatment
(Figure 3a). The percentages of necrotic area in s.c. tumours,
calculated from the image analysis technique, are presented
in Table II. There was a highly significant increase in the
amount of necrosis seen in treated tumours in comparison
with controls in both NMRI and nude hosts. Mean values in
nude mice were 84% for a dose of 25 mg kg-' 5,6-MeXAA
and 80% for 28mg kg-' as compared with control levels of
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Fie 2 (a) Assessment of 5,6-MeXAA (25 mg kg-') against
MAC15A tumours grown subcutaneously in nude mice (0, con-
trol; 0, treated). Graphs represent mean relative tumour volume.
(b) Influence of 5,6-MeXAA (28 mg kg-') against MAC1SA
tumours grown subcutaneously in NMRI mice (-0 control; 0.
treated). Graphs represent mean relative tumour volume.
11%. These were similar to those observed in NMRI mice
with 9.2%, 97% and 89% area necrosis observed in control
tumours and tumours treated with 25 mg kg-' 5,6-MeXAA
and 28 mg kg-' 5,6-MeXAA respectively.
Tumour blood volume measurements as assessed by the
Evans blue dye perfusion assay are presented in Tables III
and IV. Data showed that tumour blood volume was reduced
on administration of 5.6-MeXAA (28 mg kg-1) in NMRI
mice from mean control levels of 23 lg g-' tumour to
18 Lgg- at 2h and 8.5igg-' at 4h. Blood volumes
remained reduced after 24 h (10 gg g-'). A similar pattern
was observed in nude mice after 30 mg kg-' 5,6-MeXAA,
23 pg g-' control levels being reduced to 11 ig g-' at 2 h and
6.1gg-g' at 4 h. Deaths occurred within 24 h at 30 mg kg-'
so the experiment was repeated at 25 mgkg-', and at this
dose level Evans blue concentration within the tumour was
reduced to a mean level of 6.3 fgg-'.
When MAC1SA tumour cells were grown i.p. in NMRI
mice, no increase in the median survival time was observed
for the group treated on day 2 (30mgkg-1, 5,6-MeXAA)
compared with the control (MST: 8.0 days, treated; 7.5 days,
control).
Activity was noted against MAC15A systemic tumours in
NMRI mice when assessed by both the comparison of MST
and the lung colony counting method (Tables V and VI).
Following 5,6-MeXAA (30mg kg-') the MST increased
significantly by 70% (P<0.01), although there was one acute
death. This dose also reduced significantly the number of
colonies counted in a separate expenment (P<0.05), but the
effect was not as prominent at the reduced dose of
27.5 mg kg'.
Histological evaluation of H&E-stained sections showed
that no necrosis was present within these tumours (Figure
3b). Necrosis was also not observed when the lung tumours
were allowed to develop for 7 days before treatment with
5,6-MeXAA at single i.p. doses of either 25 mg kg-',
28 mg kg-l or 30 mg kg-'.
Discusio
This study set out to evaluate further the preclinical activity
of 5,6-MeXAA with a view to providing additional inform-
ation which might guide future clinical investigations; in
particular, it was important to investigate the compound in
situations in which FAA was ineffective. Previous studies
have demonstrated increased potency compared with FAA
(Rewcastle et al., 1991a) and increased activity against colon
38 tumours in nude mice (Ching et al., 1992). However, the
colon 38 is also moderately responsive to the clinically inac-
tive FAA in nude mice, so its in vivo responsiveness to this
class of compound suggests that it may not be the most
appropriate model to use for predicting potential clinical
activity. Previous studies in this laboratory demonstrated
MAC15A to be a useful model for assessing influence of
tumour site on chemotherapeutic response and also showed
FAA to be inactive against systemic tumour deposits (Bibby
et al., 1989a). The present investigation has addressed the
question of direct cytotoxicity by initially carrying out a
limited in vitro screen against four cell lines. The murine
colon cell line (MAC1SA) tested was much more sensitive to
5,6-MeXAA than to FAA in a 96 h MIT assay, but this
difference was not seen for the human cell lines. The
significance of this observation is not yet established and the
study needs to be extended to include additional cell lines
from each species.
Examination of the effects of 5,6-MeXAA against the sen-
sitive MAC15A cell line transplanted s.c. into NMRI mice
confirmed the earlier colon 38 data in that dramatic tumour
growth delays were seen. However, unlike the colon 38, no
anti-tumour effects were detected in nude hosts by tumour
volume measurements. More detailed study of the effects of
5,6-MeXAA revealed a similar degree of vascular shutdown
in both hosts. Objective measurements of necrosis failed to
reveal any differences between treated tumours in either host,PruinicM actvity of S6eXAA
AL Laws etal
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Figue 3 Histological appearance of treated tumours (28 mg kg-' 5,6-MeXAA). (a) Haemorrhagic necrosis in subcutaneous
tumours: (i) untreated. (ii) treated. (b) Lung deposits of MAC15A cells from responding animals showing normal morphological
appearance.
with similar massive haemorrhagic necrosis being seen in
each case. In this respect 5,6-MeXAA appears similar to
FAA (Bibby et al.. 1991).
It is likely that better tumour models of the actual clinical
targets for chemotherapy might better predict clinical out-
come, but although inoculation of a cell suspension into a
mouse has clear limitations in this respect it does at least give
the opportunity to assess some aspects of systemic disease.
As outlined earlier, FAA was shown to be inactive against
MAC15A cells grown within the peritoneal cavity or
systemically (Bibby et al., 1989a), although there were
dramatic anti-tumour effects when the same cell line was
allowed to develop into established s.c. tumours. Since FAA
has also been shown to be inactive in the clinic, it was
thought that additional useful information on 5,6-MeXAA
might be obtained by evaluating it against i.p. and i.v.
inoculated cells, initially in syngeneic hosts, in addition to
studies on s.c. tumours. This study showed the compound to
be inactive against i.p. tumour cells, although activity was
seen when the i.v. model was examined, suggesting that the
increased potency of 5,6-MeXAA over FAA might be a
useful property. Histological examination of lung depositspidlci DJ 5
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from either control mice or those treated with (and respon-
ding to) 5,6-MeXAA failed to reveal any signs of haemorr-
hagic necrosis. A further experiment allowed tmour nodules
to develop for 7 days before treatment, but these also did not
become necrotic. It is important to realis that even in these
more established tumour nodules there is no neovasculature
and the deposits are smaler than the s.c. tumours treated in
these studies. Survival studies have not been carried out
against these more advanced systemic tumours. The observa-
tions to date provide evidence that the mechanism of action
against systemic (lung) deposits is different from, or at least
lacks some of the features of, that occurring against s.c.
Table H Percentage are necrosis ofs.c. MAC15A tumours 24h after
treatment with 5,6-MeXAA as assessed by image analysis
Area ofnecrosis (%), mean ± s.dL
Treatmet NMRI mice Nude mice
Untreated 9.2 7.9 11 8.9
25mgkg-' 97 5* 84+23*
28 mg kg ' 89 17* 80 7*
*P<0.o01.
Tablem Theinfluenceof5,6-MeXAA(28 mgkg-')on tumourblood
perfusion (MACI5A) assessed by intravenous administration ofEvans
blue dye in NMRI mice
Tine after treatmnt
Untreated
2h
4h
24 h
Evans ble concentration
(pgg ')
23±3
18±3
8.5 ± 1.1*
10±2*
*P<o.001.
Table IV The influence of 5,6-MeXAA on tumour blood perfusion
(MACI5A)assessed byintravenousadministration ofEvansbluedyein
NCR nude mice
Time after treament
Untreated
2h
4h
24h
Evans bhc concetration
( '
30 mg kg-' 25 mgkg-'
MeXAA MeXAA
23±10 23±10
11±2 15±1
6.1 ±2* 12± 1
Toxc 6.3 ± 1.4*
*P<0.05.
Table V The influence of5,6-MeXAA on mice bearingintravenously
administed MAC15A cels (median survival times)
Survival time Median surival
Treatment (days) time (days) T/C%
Control 9, 10, 10, 10, 10 10
5,6-MeXAA 0, 13, 16, 18, 18 17 170*
(30.0 mg kg-')
*P<O.01.
tumours. One of the major components in the mechanism of
action against s.c. tumours is vascular shutdown, but there
was no evidence in this study of vascular shutdown in lung
deposits, possibly because of differences in blood supply to
the deposits in this site (Bibby and Double, 1993). Future
studies will address the role of tumour vasculature in
systic die in this context.
It is clear that immunomodulation is involved in the
mechanism ofaction ofFAA in mice (reviewed by Bibby and
Double, 1993), and the relevance of this to clnical disease
remains to be establshed. Futami et al. (1991) compared the
expression of cytoline genes in murine splenic leucocytes
with human peripheral blood leucocytes, and their results
demonstrated direct stimulation of cytokine gene expression
in mouse but not in human leucocytes. They concluded that
the failure of FAA to induce profound immunomodulation
or therapeutic responses in man may relate to inherent
differences in sensitivity between mouse and human cells.
Preliminary data from this laboratory (Patel et al., 1994)
have demonstrated 5,6-MeXAA to be more effective than
FAA at inducng TNF production from murine macrophages
and spleocytes in vitro, and Ching et al. (1994) have demon-
strated induction of TNF-a messenger RNA in human and
murine sells, whereas FAA was effective only in murine cells.
T1he relvance of these observations to possible in vivo
activity in man needs to be addressed.
In conclusion, 5,6-MeXAA is substantially more potent
than FAA in vitro against a mouse colon tumour cell line but
is of only equal effectiveness against three human cell lines
tested. The sensitive murne cell line produces established s.c.
tumours which are highly responsive to 5,6-MeXAA in
syngeneic hosts, but this activity is lost in nude hosts even
though blood flow shutdown and haemorrhagic necrosis still
occur. As with FAA there appears to be a very narrow
therapeutic window, with activity being seen only close to
maximum tolerated dose in each host. Anti-tumour effects
are similar against s.c. tumours in NMRI mice. Maximum
tolerated doses were marginally higher in NMRI than in
nude hosts. Tumour cells inoculated i.p. fail to respond to
the compound, even though in vitro studies showed the cells
to be very sensitive to the compound. This is possibly due to
insufficent drug exposure within the peritoneal cavity,
although pharmaciic studies would be needed to sub-
stantiate this proposal. Clearly, as these cells grow as ascites,
a vascular component cannot be involved. 5,6-MeXAA,
unlike FAA, causes anti-tumour effects in an i.v. model, but
the mechanism of action aginst this target appears different
from that occurring against s.c. tumours and probably
reflects the increased potency of the compound against this
cell ine. This increased potency will not be as useful against
cel lines that are inhertly resstant to 5,6-MeXAA, so a
study of in vitro cytotoxicity against a number of cell lines
reflecting different histological tumour types is being under-
taken. A comparison of these data with in vivo activity
against the same lines at clinically relevant anatomical sites
might be useful for selecting likely clinical targets for this
compound.
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Table VI The influence of 5,6-MeXAA on mice bearing intravenously
administered MAC15A cells (colony counting method)
Signiance
Treatment Number ofcolonies per mouse (Mann-Whitney)
Control 43, 44, 53, 83, 94, 97, 100, 103
5,6-MeXAA 21, 24, 27, 31, 32, 35, 55, 112, 137 Not signifcant
(27.5 mgkg-')
5,6-MeXAA 16, 20, 20, 21, 37, 40, 58, 86, 104 P<0.05
(30.0 mgkg-')PredinicA actvityof5AMeXAM
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